东阳光药今日港股上市

Group 1 - Dongyangguang Pharmaceutical Co., Ltd. (东阳光药) successfully listed on the Hong Kong Stock Exchange on August 7, marking a milestone in its 20-year history and a significant step for Chinese innovative pharmaceutical companies in asset securitization and internationalization [1] - The company achieved overall listing through the absorption merger of its Hong Kong subsidiary, Yichang Dongyangguang Changjiang Pharmaceutical Co., Ltd., breaking traditional capital operation time barriers and reducing funding friction costs [1] - Chairman Zhang Yingjun stated that the successful integration will accelerate the consolidation of quality resources and promote the commercialization and globalization of innovative drug pipelines, enhancing the company's core competitiveness in the global pharmaceutical market [1] Group 2 - Dongyangguang Pharmaceutical is a comprehensive pharmaceutical company engaged in drug research, production, and commercialization, focusing on three major areas: infections, chronic diseases, and tumors [2] - The company has a research and development team of over 1,100 people, with a strong R&D capability, holding more than 150 approved drugs globally and nearly 50 innovative drugs in development [2] - In the first half of this year, the Hong Kong pharmaceutical IPO market saw breakthroughs in both quantity and total fundraising, with companies like Dongyangguang Pharmaceutical expected to gain a more significant position in the global market as policies continue to deepen [2]